Table 1 Characteristics of patients treated with glatiramer acetate (GA), January 2004 – October 2013
Total patients (n = 155) | Treatment-naive (n = 100) | Previous treatment with interferon (n = 55) | P | |
|---|---|---|---|---|
Age: range, y | 17 – 60 | 17 – 56 | 24 – 60 | p = 0.3 |
Mean (± s.d.) | 37 (± 9) | 37 (± 9) | 38 (± 8) | |
Female sex, n (%) | 106 (68.3) | 73 (73.0) | 32 (58.1) | p = 0.07 |
Geographical origin | ||||
South Europe (Spain), n (%) | 145 (93.5) | 94 (94.0) | 51 (92.7) | |
Eastern Europe, n (%) | 2 (2.0) | 1 (1.8) | ||
North Africa, n (%) | 2 (2.0) | 1 (1.8) | ||
South America, n (%) | 2 (2.0) | 2 (3,6) | ||
Time to treatmenta: Mean (± s.d.), y | 5.2 (± 5.9) | 2.7 (±5.5) | 6.7 (± 5.7) | p < 0.001 |
EDSS at GA initiation (median [IQR]) | 1.5 [1–3]b | 2 [1–3]b | p = 0.2 |